Bryan M. Reasons Insider Trading Transactions

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for Bryan M. Reasons.

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of Bryan M. Reasons. Bryan M. Reasons is Chief Financial Officer in IMPAX LABORATORIES INC ($IPXL) and Director in Aclaris Therapeutics, Inc. ($ACRS) and EVP & CFO in Mallinckrodt plc ($MNK) and Director in Recro Pharma, Inc. ($REPH) and CFO in Amneal Pharmaceuticals, Inc. ($AMRX).

Latest Insider Trading Transactions of Bryan M. Reasons

1 Week2 Weeks1 Month3 Months6 Months1 Year2 Years
No. of Purchases0000000
Value of Purchases ($)0000000
No. of Sales0000000
Value of Sales ($)0000000

Sentiment: All, ACRS, AMRX, IPXL, MNK, REPH

Page:   1

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
Apr 22 2021REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseA1.7138,01265,00138,012
Apr 22 2021REPHRecro Pharma, Inc.Reasons Bryan M.DirectorGrantA0.0026,923067,42940.5 K to 67.4 K (+66.47 %)
Dec 07 2020MNKMallinckrodt plcReasons Bryan M.EVP & CFOSellS0.175,40089111,59317 K to 11.6 K (-31.78 %)
Jun 08 2020ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorOption ExerciseM0.007,33300
Jun 08 2020ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorOption ExerciseA1.4116,50023,26516,500
Jun 08 2020ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorBuyM0.007,333016,2098.9 K to 16.2 K (+82.62 %)
May 11 2020REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseA8.3712,405103,83012,405
May 11 2020REPHRecro Pharma, Inc.Reasons Bryan M.DirectorGrantA0.008,363040,50632.1 K to 40.5 K (+26.02 %)
Apr 03 2020MNKMallinckrodt plcReasons Bryan M.EVP & CFOPayment of ExerciseF1.939861,90316,99318 K to 17 K (-5.48 %)
Mar 04 2020ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorOption ExerciseM0.008,87600
Mar 04 2020ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorOption ExerciseA0.008,87608,876
Mar 04 2020ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorBuyM0.008,87608,8760 to 8.9 K
Dec 09 2019REPHRecro Pharma, Inc.Reasons Bryan M.DirectorGrantA0.009,156032,14323 K to 32.1 K (+39.83 %)
Jun 10 2019ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorOption ExerciseA0.007,33307,333
Jun 07 2019MNKMallinckrodt plcReasons Bryan M.EVP & CFOBuyP8.965,40048,38317,97912.6 K to 18 K (+42.93 %)
May 10 2019REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseA8.8010,88895,81410,888
May 10 2019REPHRecro Pharma, Inc.Reasons Bryan M.DirectorGrantA0.007,955022,98715 K to 23 K (+52.92 %)
Apr 03 2019MNKMallinckrodt plcReasons Bryan M.EVP & CFOOption ExerciseA22.2657,5691,281,48657,569
Apr 03 2019MNKMallinckrodt plcReasons Bryan M.EVP & CFOGrantA0.0012,579012,5790 to 12.6 K
Aug 23 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOSellS23.6511,698276,65882,98694.7 K to 83 K (-12.35 %)
Aug 23 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOSellS23.6511,698276,65882,98694.7 K to 83 K (-12.35 %)
May 14 2018REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseM0.008,84900
May 14 2018REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseM0.008,84900
May 14 2018REPHRecro Pharma, Inc.Reasons Bryan M.DirectorBuyM0.008,849015,0326.2 K to 15 K (+143.12 %)
May 14 2018REPHRecro Pharma, Inc.Reasons Bryan M.DirectorBuyM0.008,849015,0326.2 K to 15 K (+143.12 %)
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA0.0033,311033,311
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA15.01136,2402,044,962136,240
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA17.9952,000935,48052,000
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA25.2455,0001,388,20055,000
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA40.7047,5001,933,25047,500
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA33.2763,0952,099,17163,095
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOOption ExerciseA9.3556,232525,76956,232
May 08 2018AMRXAmneal Pharmaceuti ...Reasons Bryan M.CFOGrantA0.0094,684094,6840 to 94.7 K
May 08 2018REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseA11.325,74264,9995,742
May 08 2018REPHRecro Pharma, Inc.Reasons Bryan M.DirectorGrantA0.006,18306,1830 to 6.2 K
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...Option ExerciseD17.9952,000935,4800
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...Option ExerciseD25.2455,0001,388,2000
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...Option ExerciseD40.7047,5001,933,2500
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...Option ExerciseD33.2763,0952,099,1710
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...Option ExerciseD9.3556,232525,7690
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...SellD0.0020,5660020.6 K to 0 (-100.00 %)
May 08 2018IPXLImpax Laboratories ...Reasons Bryan M.Chief Financial Off ...SellD0.0053,4230053.4 K to 0 (-100.00 %)
Apr 23 2018ACRSAclaris Therapeuti ...Reasons Bryan M.DirectorOption ExerciseA17.7316,000283,68016,000
Mar 05 2018IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF19.503,06959,84694,68497.8 K to 94.7 K (-3.14 %)
Feb 27 2018IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF20.956,141128,65497,753103.9 K to 97.8 K (-5.91 %)
May 16 2017IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF16.804547,627103,894104.3 K to 103.9 K (-0.44 %)
May 16 2017IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF17.6570512,443104,348105.1 K to 104.3 K (-0.67 %)
Mar 06 2017REPHRecro Pharma, Inc.Reasons Bryan M.DirectorOption ExerciseA7.6320,000152,60020,000
Mar 06 2017IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Option ExerciseA9.3556,232525,76956,232
Mar 06 2017IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...GrantA0.0023,2720105,05381.8 K to 105.1 K (+28.46 %)
Feb 27 2017IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF14.055,71580,29681,78187.5 K to 81.8 K (-6.53 %)
Oct 27 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF21.351,20925,81287,49688.7 K to 87.5 K (-1.36 %)
May 16 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF29.181,21635,48388,70589.9 K to 88.7 K (-1.35 %)
May 16 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF29.181,88955,12189,92191.8 K to 89.9 K (-2.06 %)
Mar 01 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Option ExerciseA33.2763,0952,099,17163,095
Mar 01 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...GrantA0.0026,113092,84566.7 K to 92.8 K (+39.13 %)
Mar 01 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF33.271,95865,14366,73268.7 K to 66.7 K (-2.85 %)
Apr 14 2016IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF35.351,03536,58791,81092.8 K to 91.8 K (-1.11 %)
Oct 27 2015IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF35.971,29946,72568,69070 K to 68.7 K (-1.86 %)
May 19 2015IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF44.441,39161,81669,98971.4 K to 70 K (-1.95 %)
May 19 2015IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF44.822,16196,85671,38073.5 K to 71.4 K (-2.94 %)
Apr 15 2015IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF50.901,20561,33573,54174.7 K to 73.5 K (-1.61 %)
Mar 12 2015IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Option ExerciseA40.7047,5001,933,25047,500
Mar 12 2015IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...GrantA0.0020,000074,74654.7 K to 74.7 K (+36.53 %)
Oct 28 2014IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF27.8094026,13254,74655.7 K to 54.7 K (-1.69 %)
May 16 2014IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Option ExerciseA25.2455,0001,388,20055,000
May 16 2014IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF25.561,40035,78455,68657.1 K to 55.7 K (-2.45 %)
May 16 2014IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...GrantA0.0023,000057,08634.1 K to 57.1 K (+67.48 %)
Apr 14 2014IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF24.551,21629,85334,08635.3 K to 34.1 K (-3.44 %)
Oct 28 2013IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF20.4793919,22135,30236.2 K to 35.3 K (-2.59 %)
May 16 2013IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Option ExerciseA17.9952,000935,48052,000
May 16 2013IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...GrantA0.0014,800036,24121.4 K to 36.2 K (+69.03 %)
Apr 16 2013IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...Payment of ExerciseF16.461,15919,07721,44122.6 K to 21.4 K (-5.13 %)
Feb 15 2013IPXLIMPAX LABORATORIES ...Reasons Bryan M.Chief Financial Off ...GrantA0.0010,000022,60012.6 K to 22.6 K (+79.37 %)

Page:   1